Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02662062
Title Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer (PCR-MIB)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group

bladder urothelial carcinoma


Cisplatin + Pembrolizumab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.